Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Spero Therapeutics Inc (SPRO)

49 + Investors. Track Smart Money conviction in SPRO. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↓ -7
Streak
1Q ▼
Buyers last Q
46%

Smart Money Signals — SPRO

Based on 49 hedge funds · latest filing: 2026 Q1 · updated quarterly

📉

Selling streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds reduced or closed their SPRO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.
📊

High ownership — 88% of 3.0Y peak

88% of all-time peak
49 funds currently hold this stock — 88% of the 3.0-year high of 56 funds (reached 2025 Q4). Ownership is elevated but not yet at maximum concentration. Room to grow, but watch if the trend reverses.
🚀

Fast accumulation — +26% more funds vs a year ago

fund count last 6Q
+10 new funds entered over the past year (+26% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks. The peak was reached in just 3 quarters from the low — a sharp move.
🟠

More sellers than buyers — 46% buying

21 buying25 selling
Last quarter: 25 funds reduced or exited vs 21 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.
⚠️

Fewer new buyers each quarter (-7 vs last Q)

new funds entering per quarter
Funds opening this position for the first time: 15 → 15 → 14 → 7. Each quarter fewer new institutions are entering. This usually means most funds that wanted in are already in — the stock is well-known but the pool of potential new buyers is shrinking.
🔒

45% of holders stayed for 2+ years

■ 45% conviction (2yr+) ■ 24% medium ■ 31% new
22 out of 49 hedge funds have held SPRO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📊

Peak discovery — momentum slowing

2 → 15 → 15 → 14 → 7 new funds/Q
New funds entering each quarter: 15 → 15 → 14 → 7. SPRO is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 63% veterans vs 28% newcomers

■ 63% veterans ■ 9% 1-2yr ■ 28% new
Entry-cohort mix of 54 holders: 34 (63%) are 2+ year veterans, 5 entered 1–2 years ago, and 15 (28%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
📋

Smaller funds dominant — 9% AUM from top-100

9% from top-100 AUM funds
16 of 49 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
3.8
out of 10
Low Exit Risk
Exit risk score 3.8/10 — low institutional crowding. Ownership is below peak levels, holder base is relatively sticky, and buying momentum is positive.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — SPRO

In 2026 Q1, 21 hedge funds were net buyers of SPRO (7 opened a new position, 14 added to an existing one), while 25 reduced or exited (11 trimmed, 14 sold completely) — a 46% buyer ratio, indicating roughly balanced activity. Net fund flow last quarter: -7 funds (more exits than new entries). Total institutional holders: 49.

Hedge Fund Ownership: SPRO

How many hedge funds hold SPRO — quarterly history vs. share price
Quarterly hedge fund ownership of SPRO vs. share price

Market Analysis: SPRO

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: SPRO

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Spero Therapeutics Inc (SPRO) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much SPRO has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
SPRO
-9.8%
XLV
+2.8%

SPRO outperformed XLV by -12.6% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
SPRO
-24.6%
XLV
+3.9%

Since the filing became public, SPRO outperformed XLV by -28.5% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

6 top-rated funds 2 high-conviction
Consensus
3.7
/ 10
breadth
×
Elite
1.3
/ 10
conviction
Hedge Fund Positioning: SPRO
49 + Investors

Track Smart Money conviction in SPRO. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 49 56 -12.5%
13F Shares 21M 21M -1.05%
Total Value $48M $49M -1.99%
New Positions 7 14 -7
Increased Positions 12 16 -4
Closed Positions 14 7 +7
Reduced Positions 10 12 -2
Total Calls 2 0 100%
Total Puts 3 2 50.0%
PUT/CALL Ratio 1.5 0.0 Bearish

Statistics: SPRO

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

49 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in SPRO. Verified SEC 13F-HR filings.

QUARTER:
Top 25 SPRO holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 GSK plc 3.59% 9,190,606 $21.5M
2 Pfizer Inc 2.31% 2,362,348 $5.5M
3 Verdad Advisers, LP 0.09% 33,455 $78K
4 Anson Funds Management LP 0.09% 421,956 $987K
5 Alphabet Inc. 0.05% 889,979 $2.1M
6 Ionic Capital Management LLC 0.03% 195,939 $458K
7 Intrepid Family Office LLC 0.03% 16,279 $38K
8 Three Seasons Wealth, LLC 0.03% 30,000 $70K
9 Torrey Growth & Income Advisors 0.02% 17,025 $38K
10 Shay Capital LLC 0.01% 70,354 $165K
11 Bridgeway Capital Management, LLC 0.01% 114,800 $269K
12 Renaissance Technologies LLC 0.00% 1,189,235 $2.8M
13 Capital Asset Advisory Services LLC 0.00% 32,548 $92K
14 Occudo Quantitative Strategies LP 0.00% 16,421 $41K
15 Two Sigma Investments, LP 0.00% 885,631 $2.1M
16 Quadrature Capital Ltd 0.00% 40,128 $94K
17 Two Sigma Advisers, LP 0.00% 216,600 $505K
18 OMERS ADMINISTRATION Corp 0.00% 39,400 $92K
19 Squarepoint Ops LLC 0.00% 194,301 $455K
20 Marshall Wace, LLP 0.00% 157,072 $368K
21 Schonfeld Strategic Advisors LLC 0.00% 20,314 $48K
22 Point72 Asset Management, L.P. 0.00% 59,668 $140K
23 Vanguard Fiduciary Trust Co 0.00% 264,115 $618K
24 Citadel Advisors LLC 0.00% 376,458 $881K
25 Vanguard Capital Management LLC 0.00% 1,799,880 $4.2M
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Spero Therapeutics Inc (SPRO)

What does the Smart Money Trend signal show for SPRO?

Selling streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds reduced or closed their SPRO positions than added to them. Sustained institutional selling is a meaningful warning sign — these are professionals with deep research teams collectively deciding to exit.

What is the institutional breadth score for SPRO?

More sellers than buyers — 46% buying: Last quarter: 25 funds reduced or exited vs 21 that bought or added. When more than half of active funds are selling, it's a caution flag — especially if the stock price hasn't moved down yet.

What is the fund quality score for SPRO holders?

Smaller funds dominant — 9% AUM from top-100: 16 of 49 holders rank in the top 100 by AUM, but together hold only 9% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held SPRO?

45% of holders stayed for 2+ years: 22 out of 49 hedge funds have held SPRO for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Spero Therapeutics Inc (SPRO) following the 2026 Q1 hedge fund 13F filings?

As of today, SPRO has moved -24.6% since the 2026 Q1 13F filing date (May 15, 2026), compared to +3.9% for the XLV sector ETF — an outperformance of -28.5%. Since the quarter end (March 31, 2026), SPRO has gained -9.8% vs +2.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →